Dajio 10mg (Dapagliflozin)

• Composition :
  Each tablet contains Dapagliflozin 10mg.
• Indications :
  In adult aged 18 years and older with Type-II diabetic mellitus to improve glycemic control: As mono-therapy when diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance. As add-on combination therapy in combination therapy in combination with other glucose- lowering medicinal products including insulin, when these, together with diet and exercise, do notprovide adequate glycemic control.
• Pharmacodynamics :
  In the proximal tubules, Sodium-glucose cotransporter 2 (SGLT2) plays a major role in reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2) that improves glycaemic control in patients with T2DM by reducing renal glucose reabsorption leading to urinary excretion of excess glucose.
• Dosage and administration :
  One tablet, once daily, with or without food.
• Contraindications :
  Patients who have a history of hypersensitivity to the Dapagliflozin. Patients with severe renal impairment, (eGFR less than 30 mL/min/1.73 m2) end-stage renal disease (ESRD), or patients on dialysis.
• Precautions and warnings :
  Caution should be exercised, while administering Dajio in patients with hypotension, ketoacidosis, acute kidney injury, urosepsis and polynephritis, hypoglycaemia, necrotizing fasciitis of the perineum (Fournier’s Gangrene) and genital myotic infections.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy: Advise females of the potential risk to a fetus especially during the second and third trimesters. Lactation: Not recommended when breastfeeding.Safety and effectiveness in paediatric patients under 18 years of age have not been established.
• Drug interactions :
  Positive Urine Glucose Test: SGLT2 inhibitors increase urine glucose, which might lead to false positive results. Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.
• Adverse reactions :
  Male and female genital mycoticinfections, hypotension, ketoacidosis, nasopharyngitis, UTI, back pain, increased micturition, nausea, constipation, dyslipidaemia and influenza.
• Therapy Area :
  Anti-Diabetic agents